MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Condition:   Acute Lymphoblastic Leukemia (ALL) Intervention:   Drug: Nilotinib Sponsor:   Novartis Pharmaceuticals Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials